Results 171 to 180 of about 46,238 (244)

Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome. [PDF]

Orphanet J Rare Dis
Zhang H, Zhai F, Su M, Zhang Y, Ma J, Zhao J, Wang J, Chang X, Liu Y, Guo J, Zhang W.   +10 more
europepmc   +1 more source

Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study. [PDF]

, 1996
Rudolf Korinthenberg, Jürgen Schulte Mönting   +1 more
openalex   +1 more source

Guillain-Barré Syndrome Mimicking Autoimmune Hepatitis: A Rare Entity. [PDF]

ACG Case Rep J
Abdelmotelib I, Rosario Lora D, Abdelhalim O, Abosheaishaa H, Eswaran S, Reau N.   +5 more
europepmc   +1 more source

A Multidisciplinary Extended Approach to Physiotherapy Rehabilitation in Guillain-Barre Syndrome as Sequelae of COVID-19: A Single Case Study

Nikita Kachhwani, Pallavi Bhakaney, Vaishnavi Yadav   +2 more
openalex   +1 more source

Guillain-Barre syndrome with posterior reversible encephalopathy syndrome [PDF]

, 2014
Basavaraj F. Banakar, Guruprasad S. Pujar, Amita Bhargava, Khichar Shubhkaran   +3 more
openalex   +1 more source

Efgartigimod in the treatment of Guillain-Barré syndrome: case report. [PDF]

Front Immunol
Deng M, Kong Z, Wang Y, Wang X, Li T.
europepmc   +1 more source

Guillain-Barre Syndrome after Kidney Transplantation: a Case Report

, 2013
Mohsen Farazdaghi, Anahita Zoghi, Afshin Borhani‐Haghighi   +2 more
openalex   +2 more sources

Comments on: "Elevated Serum Amyloid A2 and A4 in Patients With Guillain-Barré Syndrome". [PDF]

J Clin Neurol
Finsterer J.
europepmc   +1 more source

Reversible Left Ventricular Dysfunction Associated with Guillain-Barre Syndrome. An Expression of Catecholamine Cardiotoxicity?

, 1995
Kanji Iga, Yoshihiro Himura, Chisato Izumi, Tadashi Miyamoto, Kazuhisa Kijima, Hiromitsu Gen, Takashi Konishi   +6 more
openalex   +2 more sources

A Rare Presentation of Guillain-Barré Syndrome: A Case Report and Literature Review. [PDF]

Cureus
De la Hoz I, White G, Sharbatji M.
europepmc   +1 more source